Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Super DC Vaccine overview
The therapeutic candidate is under development for the treatment of advanced solid tumors. It comprises of dendritic cells and is administered through parenteral route.
Shanghai Cell Therapy Group overview
Shanghai Cell Therapy Group, is a biotechnology company that develops tumour immune cell therapy treatments. The company is headquartered in China.
For a complete picture of Super DC Vaccine’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Super #Vaccine #Shanghai #Cell #Therapy #Group #Solid #Tumor #Likelihood #Approval
